News
-
-
-
-
PRESS RELEASE
Newron to present new analyses from and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 38th ECNP Congress 2025
Newron Pharmaceuticals to present new analyses and updates on evenamide as treatment for schizophrenia at the 38th ECNP Congress 2025 -
-
PRESS RELEASE
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron. Commercial launch expected in Q4/2026 -
-
PRESS RELEASE
CORRECTION FROM SOURCE: Early Warning News Release Regarding the Acquisition of Over 10% of the Common Shares of Alset AI Ventures Inc.
Alset AI Ventures Inc. announces acquisition of 1,807,153 common shares by Mr. Randy Gilling. The Acquiror now holds 10.82% of the company's shares. More details in the press release -
-